GB2271121A — New aspergillus niger mutants and assay for immunosuppressants
Assigned to Merck and Co Inc · Expires 1994-04-06 · 32y expired
What this patent protects
Aspergillus niger mutants which can identify active FK-506/rapamycin type, or cyclosporin A type immunosuppressants or composition exhibiting immunosuppressant activity are disclosed. Specifically disclosed are the mutants, ATCC No. 74085 (MF 5659), which is sensitive to FK-506 a…
USPTO Abstract
Aspergillus niger mutants which can identify active FK-506/rapamycin type, or cyclosporin A type immunosuppressants or composition exhibiting immunosuppressant activity are disclosed. Specifically disclosed are the mutants, ATCC No. 74085 (MF 5659), which is sensitive to FK-506 and rapamycin but resistant to cyclosporin A; ATCC No. 74086 (MF 5659) which is resistant to FK-506, cyclosporin A and rapamycin; and ATCC No. 74087 (MF 5661) which is resistant to FK-506 and rapamycin, but sensitive to cyclosporin A. Resistant strains lack proteins which bind to the immunosuppressant compounds.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.